Nektar Therapeutics (NKTR)
37.22
-1.43
(-3.70%)
USD |
NASDAQ |
Oct 23, 16:00
37.23
+0.01
(+0.03%)
After-Hours: 20:00
Nektar Therapeutics Enterprise Value : 721.90M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 721.90M |
| October 22, 2026 | 770.71M |
| October 21, 2026 | 757.74M |
| October 20, 2026 | 790.16M |
| October 19, 2026 | 702.11M |
| October 16, 2026 | 672.75M |
| October 15, 2026 | 738.97M |
| October 14, 2026 | 710.64M |
| October 13, 2026 | 745.79M |
| October 12, 2026 | 811.32M |
| October 09, 2026 | 856.71M |
| October 08, 2026 | 844.08M |
| October 07, 2026 | 825.65M |
| October 06, 2026 | 813.71M |
| October 05, 2026 | 892.55M |
| October 02, 2026 | 938.97M |
| October 01, 2026 | 1.055B |
| September 30, 2026 | 1.518B |
| September 29, 2026 | 1.473B |
| September 28, 2026 | 1.513B |
| September 25, 2026 | 1.399B |
| September 24, 2026 | 1.478B |
| September 23, 2026 | 1.420B |
| September 22, 2026 | 1.532B |
| September 21, 2026 | 1.733B |
| Date | Value |
|---|---|
| September 18, 2026 | 1.742B |
| September 17, 2026 | 1.785B |
| September 16, 2026 | 1.751B |
| September 15, 2026 | 1.726B |
| September 14, 2026 | 1.789B |
| September 11, 2026 | 1.832B |
| September 10, 2026 | 1.863B |
| September 09, 2026 | 1.954B |
| September 08, 2026 | 2.026B |
| September 04, 2026 | 1.984B |
| September 03, 2026 | 2.058B |
| September 02, 2026 | 1.934B |
| September 01, 2026 | 1.900B |
| August 31, 2026 | 1.888B |
| August 28, 2026 | 1.927B |
| August 27, 2026 | 1.996B |
| August 26, 2026 | 1.969B |
| August 25, 2026 | 2.010B |
| August 24, 2026 | 1.967B |
| August 21, 2026 | 1.978B |
| August 20, 2026 | 1.995B |
| August 19, 2026 | 2.048B |
| August 18, 2026 | 1.965B |
| August 17, 2026 | 1.932B |
| August 14, 2026 | 1.944B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Eli Lilly & Co. | 1.245T |
| Inovio Pharmaceuticals, Inc. | 45.20M |
| Tonix Pharmaceuticals Holding Corp. | -88.14M |
| Capricor Therapeutics, Inc. | 197.70M |
| Kyntra Bio, Inc. | -50.77M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -40.62M |
| Revenue (Quarterly) | 10.13M |
| Total Expenses (Quarterly) | 50.75M |
| EPS Diluted (Quarterly) | -1.229 |
| Gross Profit Margin (Quarterly) | 98.46% |
| Profit Margin (Quarterly) | -401.0% |
| Earnings Yield | -17.99% |
| Normalized Earnings Yield | -17.09 |